Enhanced Insulin Secretion Through Upregulation of Transcription Factors by Hydroalcoholic Extract of Securigera securidaca Seeds in Diabetic Animal Model.
Animals
Plant Extracts
/ pharmacology
Diabetes Mellitus, Experimental
/ metabolism
Rats
Seeds
/ chemistry
Insulin Secretion
/ drug effects
Insulin
/ metabolism
Male
Up-Regulation
Securidaca
Oxidative Stress
/ drug effects
Rats, Wistar
NF-E2-Related Factor 2
/ metabolism
Transcription Factors
/ metabolism
Fibroblast Growth Factors
/ metabolism
Pancreas
/ metabolism
Antioxidants
/ pharmacology
Liver
/ metabolism
Trans-Activators
Homeodomain Proteins
Securigera securidaca
FGF21
MafA
Nrf2
PDX1
diabetes
insulin
Journal
Endocrinology, diabetes & metabolism
ISSN: 2398-9238
Titre abrégé: Endocrinol Diabetes Metab
Pays: England
ID NLM: 101732442
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
19
07
2024
received:
14
05
2024
accepted:
28
07
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
ppublish
Résumé
In previous studies, the researchers observed an increase in insulin secretion in STZ-treated diabetic rats following treatment with the hydroalcoholic extract of Securigera securidaca (HESS) seeds. This study focuses on the relationship between the antioxidant properties of HESS with changes in diabetic pancreatic tissue and the gene expression of factors that impact insulin secretion. In this controlled experimental study, three varying doses of HESS were administered to three groups of diabetic rats induced by STZ. Oxidative stress indicators like total antioxidant capacity (TAC), total oxidant status (TOS) and malondialdehyde were assessed in both pancreatic and liver tissues. Pancreatic histology was studied post-haematoxylin staining. Insulin and FGF21 levels in the blood were measured using the ELISA method. The expression of Nrf2 and FGF21 genes in the pancreas and liver, along with MafA and PDX-1 genes in the pancreas, was quantified using real-time PCR. The administration of HESS in varying doses led to a dose-dependent rise in blood insulin levels and a decrease in blood glucose levels and oxidative stress. By reducing oxidative stress, HESS treatment lowered the heightened levels of NRF2 and FGF21 in the liver and pancreas of diabetic rats, improving pancreatic tissue health. As oxidative stress decreased, the expression of MafA and PDX1 genes in the pancreas approached levels seen in healthy rats. HESS elicits an increase in insulin secretion through the mitigation of oxidative stress and tissue damage, as well as the modulation of gene expression related to the insulin transcription factors PDX-1 and MafA.
Substances chimiques
Plant Extracts
0
Insulin
0
fibroblast growth factor 21
0
NF-E2-Related Factor 2
0
Transcription Factors
0
Fibroblast Growth Factors
62031-54-3
pancreatic and duodenal homeobox 1 protein
0
Antioxidants
0
Trans-Activators
0
Homeodomain Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e515Subventions
Organisme : Iran University of Medical Sciences
ID : 17152
Informations de copyright
© 2024 The Author(s). Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Références
A. P. Alves, A. C. Mamede, M. G. Alves, et al., “Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?,” Current Cancer Drug Targets 19, no. 1 (2019): 26–40.
P. Rorsman and F. M. Ashcroft, “Pancreatic β‐Cell Electrical Activity and Insulin Secretion: Of Mice and Men,” Physiological Reviews 98, no. 1 (2018): 117–214.
S. Alizadeh‐Fanalou, M. Babaei, A. Hosseini, et al., “Effects of Securigera securidaca Seed Extract in Combination With Glibenclamide on Antioxidant Capacity, Fibroblast Growth Factor 21 and Insulin Resistance in Hyperglycemic Rats,” Journal of Ethnopharmacology 248 (2020): 112331.
A. Nahdi, A. John, and H. Raza, “Elucidation of Molecular Mechanisms of Streptozotocin‐Induced Oxidative Stress, Apoptosis, and Mitochondrial Dysfunction in Rin‐5F Pancreatic β‐Cells,” Oxidative Medicine and Cellular Longevity 2017 (2017): 7054272.
M. L. Graham, J. L. Janecek, J. A. Kittredge, B. J. Hering, and H. J. Schuurman, “The Streptozotocin‐Induced Diabetic Nude Mouse Model: Differences Between Animals From Different Sources,” Comparative Medicine 61, no. 4 (2011): 356–360.
P. Pacher and C. Szabó, “Role of Poly(ADP‐Ribose) polymerase‐1 Activation in the Pathogenesis of Diabetic Complications: Endothelial Dysfunction, as a Common Underlying Theme,” Antioxidants & Redox Signaling 7, no. 11–12 (2005): 1568–1580.
S.‐H. Abtahi‐Evari, M. Shokoohi, A. Abbasi, A. Rajabzade, H. Shoorei, and H. Kalarestaghi, “Protective Effect of Galega Officinalis Extract on Streptozotocin‐Induced Kidney Damage and Biochemical Factor in Diabetic Rats,” Crescent Journal of Medical and Biological Sciences 4 (2017): 108–114.
M. E. Cerf, “Beta Cell Dysfunction and Insulin Resistance,” Frontiers in Endocrinology 4 (2013): 37.
U. Asmat, K. Abad, and K. Ismail, “Diabetes Mellitus and Oxidative Stress‐A Concise Review,” Saudi Pharmaceutical Journal 24, no. 5 (2016): 547–553.
S.‐H. Abtahi‐Eivari, M. Shokoohi, M. Ghorbani, et al., “Effects of Hydroalcoholic Extracts of Cloves (Syzygium aromaticum) on the Serum Biomarkers, Antioxidant Status, and Histopathological Changes of Kidneys in Diabetic Rats,” Crescent Journal of Medical & Biological Sciences 8, no. 4 (2021): 269–275.
D. B. Zorov, M. Juhaszova, and S. J. Sollott, “Mitochondrial Reactive Oxygen Species (ROS) and ROS‐Induced ROS Release,” Physiological Reviews 94, no. 3 (2014): 909–950.
Y. Zhu, Q. Liu, Z. Zhou, and Y. Ikeda, “PDX1, Neurogenin‐3, and MAFA: Critical Transcription Regulators for Beta Cell Development and Regeneration,” Stem Cell Research & Therapy 8, no. 1 (2017): 240.
D. D. Zhang and M. Hannink, “Distinct Cysteine Residues in Keap1 Are Required for Keap1‐Dependent Ubiquitination of Nrf2 and for Stabilization of Nrf2 by Chemopreventive Agents and Oxidative Stress,” Molecular and Cellular Biology 23, no. 22 (2003): 8137–8151.
S. Dayalan Naidu, A. Muramatsu, R. Saito, et al., “C151 in KEAP1 Is the Main Cysteine Sensor for the Cyanoenone Class of NRF2 Activators, Irrespective of Molecular Size or Shape,” Scientific Reports 8, no. 1 (2018): 8037.
Y. Yu, J. He, S. Li, et al., “Fibroblast Growth Factor 21 (FGF21) inhibits Macrophage‐Mediated Inflammation by Activating Nrf2 and Suppressing the NF‐κB Signaling Pathway,” International Immunopharmacology 38 (2016): 144–152.
Y. Furusawa, A. Uruno, Y. Yagishita, C. Higashi, and M. Yamamoto, “Nrf2 Induces Fibroblast Growth Factor 21 in Diabetic Mice,” Genes to Cells 19, no. 12 (2014): 864–878.
S. Alizadeh‐Fanalou, A. Nazarizadeh, M. Babaei, M. Khosravi, N. Farahmandian, and E. Bahreini, “Effects of Securigera securidaca (L.) Degen & Dorfl Seed Extract Combined With Glibenclamide on paraoxonase1 Activity, Lipid Profile and Peroxidation, and Cardiovascular Risk Indices in Diabetic Rats,” BioImpacts 10, no. 3 (2020): 159–167.
H. K. Aldal'in, G. Al‐Mazaideh, A. H. Al‐Nadaf, et al., “Phytochemical Constituents of Securigera securidaca Seed Extract Using GS‐MS and HPLC,” Tropical Journal of Natural Product Research 4, no. 9 (2020): 540–544.
M. Soleimani‐Dodran, R. Alipanah‐Moghadam, F. Jeddi, M. Babaei, R. Salimnejad, and E. Bahreini, “Effect of Hydroalcoholic Seed Extract of Nigella Sativa on Hepatic and Pancreatic Factors of Nrf2 and FGF21 in the Regulation of Insulin Transcription Factors of MafA and PDX‐1 in Streptozotocin‐Treated Diabetic Rats,” Nutrition & Metabolism 19, no. 1 (2022): 64.
S. Chandra, S. Khan, B. Avula, et al., “Assessment of Total Phenolic and Flavonoid Content, Antioxidant Properties, and Yield of Aeroponically and Conventionally Grown Leafy Vegetables and Fruit Crops: A Comparative Study,” Evidence‐Based Complementary and Alternative Medicine 2014 (2014): 253875.
V. L. Singleton, R. Orthofer, and R. M. Lamuela‐Raventós, “Analysis of Total Phenols and Other Oxidation Substrates and Antioxidants by Means of Folin‐Ciocalteu Reagent,” in Methods in Enzymology. vol. 299 (Cambridge, MA: Academic Press, 1999), 152–178.
X. Zhang and P. Hartmann, “How to Calculate Sample Size in Animal and Human Studies,” Frontiers in Medicine 10 (2023): 1215927.
R. Sudan, M. Bhagat, S. Gupta, J. Singh, and A. Koul, “Iron (FeII) Chelation, Ferric Reducing Antioxidant Power, and Immune Modulating Potential of Arisaema jacquemontii (Himalayan Cobra Lily),” BioMed Research International 2014 (2014): 179865.
C. Y. Hsieh, C. L. Chen, K. C. Yang, C. T. Ma, P. C. Choi, and C. F. Lin, “Detection of Reactive Oxygen Species During the Cell Cycle Under Normal Culture Conditions Using a Modified Fixed‐Sample Staining Method,” Journal of Immunoassay & Immunochemistry 36, no. 2 (2015): 149–161.
Y. J. Garcia, A. J. Rodríguez‐Malaver, and N. Peñaloza, “Lipid Peroxidation Measurement by Thiobarbituric Acid Assay in Rat Cerebellar Slices,” Journal of Neuroscience Methods 144, no. 1 (2005): 127–135.
H. N. Yousef, S. M. Sakr, and S. A. Sabry, “Mesenchymal Stem Cells Ameliorate Hyperglycemia in Type I Diabetic Developing Male Rats,” Stem Cells International 2022 (2022): 7556278.
S. Mathew, T. E. Abraham, and Z. A. Zakaria, “Reactivity of Phenolic Compounds Towards Free Radicals Under in Vitro Conditions,” Journal of Food Science and Technology 52, no. 9 (2015): 5790–5798.
R. K. Al‐Ishaq, M. Abotaleb, P. Kubatka, K. Kajo, and D. Büsselberg, “Flavonoids and Their Anti‐Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels,” Biomolecules 9, no. 9 (2019): 430.
G. Williamson and K. Sheedy, “Effects of Polyphenols on Insulin Resistance,” Nutrients 12, no. 10 (2020): 3135.
Z. Sun, Z. Huang, and D. D. Zhang, “Phosphorylation of Nrf2 at Multiple Sites by MAP Kinases Has a Limited Contribution in Modulating the Nrf2‐Dependent Antioxidant Response,” PLoS One 4, no. 8 (2009): e6588.
D. V. Chartoumpekis, P. G. Ziros, A. I. Psyrogiannis, et al., “Nrf2 Represses FGF21 During Long‐Term High‐Fat Diet‐Induced Obesity in Mice,” Diabetes 60, no. 10 (2011): 2465–2473.
Y. Cheng, J. Zhang, W. Guo, et al., “Up‐Regulation of Nrf2 Is Involved in FGF21‐Mediated Fenofibrate Protection Against Type 1 Diabetic Nephropathy,” Free Radical Biology & Medicine 93 (2016): 94–109.
Y. Pan, B. Wang, J. Zheng, et al., “Pancreatic Fibroblast Growth Factor 21 Protects Against Type 2 Diabetes in Mice by Promoting Insulin Expression and Secretion in a PI3K/Akt Signaling‐Dependent Manner,” Journal of Cellular and Molecular Medicine 23, no. 2 (2019): 1059–1071.
S. Baumel‐Alterzon, L. S. Katz, L. Lambertini, et al., “NRF2 Is Required for Neonatal Mouse Beta Cell Growth by Maintaining Redox Balance and Promoting Mitochondrial Biogenesis and Function,” Diabetologia 67, no. 3 (2024): 547–560.
Z. Chen, L. Yang, Y. Liu, P. Huang, H. Song, and P. Zheng, “The Potential Function and Clinical Application of FGF21 in Metabolic Diseases,” Frontiers in Pharmacology 13 (2022): 1089214.
L. R. Cataldo, N. Vishnu, T. Singh, et al., “The MafA‐Target Gene PPP1R1A Regulates GLP1R‐Mediated Amplification of Glucose‐Stimulated Insulin Secretion in β‐Cells,” Metabolism 118 (2021): 154734.
D. Garcia and R. J. Shaw, “AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance,” Molecular Cell 66, no. 6 (2017): 789–800.
J. Liu, G. Lang, and J. Shi, “Epigenetic Regulation of PDX‐1 in Type 2 Diabetes Mellitus,” Diabetes, Metabolic Syndrome and Obesity 14 (2021): 431–442.
S. Ferber, A. Halkin, H. Cohen, et al., “Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin‐Induced Hyperglycemia,” Nature Medicine 6, no. 5 (2000): 568–572.
H. Kaneto, T. Miyatsuka, Y. Fujitani, et al., “Role of PDX‐1 and MafA as a Potential Therapeutic Target for Diabetes,” Diabetes Research and Clinical Practice 77, no. 3 Supple (2007): S127–S137.
T. Kondo, I. El Khattabi, W. Nishimura, et al., “p38 MAPK Is a Major Regulator of MafA Protein Stability Under Oxidative Stress,” Molecular Endocrinology 23, no. 8 (2009): 1281–1290.
I. El Khattabi and A. Sharma, “Preventing p38 MAPK‐Mediated MafA Degradation Ameliorates β‐Cell Dysfunction Under Oxidative Stress,” Molecular Endocrinology 27, no. 7 (2013): 1078–1090.
H. Chen, S. Brahmbhatt, A. Gupta, and A. C. Sharma, “Duration of Streptozotocin‐Induced Diabetes Differentially Affects p38‐Mitogen‐Activated Protein Kinase (MAPK) phosphorylation in Renal and Vascular Dysfunction,” Cardiovascular Diabetology 4, no. 1 (2005): 3.
M.‐J. Stahnke, C. Dickel, S. Schröder, et al., “Inhibition of Human Insulin Gene Transcription and MafA Transcriptional Activity by the Dual Leucine Zipper Kinase,” Cellular Signalling 26, no. 9 (2014): 1792–1799.
Y. I. Kitamura, T. Kitamura, J.‐P. Kruse, et al., “FoxO1 Protects Against Pancreatic β Cell Failure Through NeuroD and MafA Induction,” Cell Metabolism 2, no. 3 (2005): 153–163.
T. Zhang, D. H. Kim, X. Xiao, et al., “FoxO1 Plays an Important Role in Regulating β‐Cell Compensation for Insulin Resistance in Male Mice,” Endocrinology 157, no. 3 (2016): 1055–1070.
M. S. Savova, L. V. Mihaylova, D. Tews, M. Wabitsch, and M. I. Georgiev, “Targeting PI3K/AKT Signaling Pathway in Obesity,” Biomedicine & Pharmacotherapy 159 (2023): 114244.
E. Hajduch, G. J. Litherland, and H. S. Hundal, “Protein Kinase B (PKB/Akt)—A Key Regulator of Glucose Transport?” FEBS Letters 492, no. 3 (2001): 199–203.
M. Kobayashi, O. Kikuchi, T. Sasaki, et al., “FoxO1 as a Double‐Edged Sword in the Pancreas: Analysis of Pancreas‐ and β‐Cell‐Specific FoxO1 Knockout Mice,” American Journal of Physiology Endocrinology and Metabolism 302, no. 5 (2012): E603–E613.